[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eosinophilic-gastritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eosinophilic-gastritis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100456887","study-of-gastric-motility-in-eosinophilic-gastritis-100456887",false,"NCT05229432","Study of Gastric Motility in Eosinophilic Gastritis","Pilot Assessment to Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders","OAT-FEED","Inclusion Criteria:\n\n* Eosinophilic gastritis (EG) defined as at least one endoscopy with histopathologic evidence of ≥ 30 eosinophils in 5 or more high powered fields (hpf's) with associated symptoms of EG.\n* Patient reported symptoms starting at least one year or more prior to screening consistent with a diagnosis of EG: nausea, vomiting, early satiety, abdominal pain\u002Fbloating, regurgitation, diarrhea.\n* Symptoms suggestive of a possible gastric motility disorder during the 60 days prior to screening including: nausea, vomiting, early satiety, post-prandial feeling of fullness or bloating.\n* Tolerance and willingness to consume the oatmeal meal in this study.\n\nExclusion Criteria:\n\n* Diagnosis of eosinophilic enteritis.\n* Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).\n* Known disorders associated with eosinophilic gastrointestinal (GI) diseases (e.g., D 816 V Kit+ systemic mastocytosis, Marfan syndrome or Loey's Dietz Syndrome).\n* Known inflammatory or autoimmune disorders associated with gastric dysmotility such as systemic sclerosis, lupus or eosinophilic fasciitis.\n* Uncontrolled diabetes or known diabetic complications of gastroparesis, neuropathy or nephropathy.\n* Taking opioid agents in the 2 weeks prior to screening and throughout the study.\n* History of strictures in the small bowel or stomach (e.g., pyloric stenosis) or gastric surgeries or procedures such as pyloromyotomy, pyloric dilation, pyloric resection, vagotomy, bariatric surgery or post-Nissen fundoplication or antrectomy with Billroth I, Billroth II or Roux-en-Y gastrojejunostomy.\n* Past or current medical problems or findings such as: advanced liver disease (Child's B or C), acute or chronic renal disease (serum creatinine \\> 3 mg\u002FdL), neurologic disease (e.g., dysautonomia), achalasia and adrenal insufficiency.","ALL","18 Years","59 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","Purpose:\n\nThe study is a cross-sectional observational study designed to determine if eosinophilic gastritis (EG) results in gastric motility impairment.\n\nHypothesis:\n\nGastric dysfunction occurs in the natural history of EG but is underdiagnosed due, in part, to contraindications to the use of the standard meals used in gastric emptying studies.",[26,27,28],"Eosinophilic Gastritis","Gastroparesis","Gastric Motility Disorder",[30,31,32,33,34,35,36,37,38,39,40,41],"Gastritis","Eosinophilic Gastrointestinal Disorders","Gastric Dysfunction","Gastric Dysmotility","Eosinophils","Eosinophilia","Eosinophilic Disorders","Digestive System Diseases","Immune System Diseases","Stomach Diseases","Gastric Emptying Scintigraphy","Endoscopy","RECRUITING","2026-03-26",{"date":45,"type":46},"2026-03-31","ACTUAL",{"date":48,"type":46},"2023-01-25",{"date":50,"type":22},"2026-12-01",{"name":52,"class":53},"Children's Hospital Medical Center, Cincinnati","OTHER",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100249239","omega-outcome-measures-in-eosinophilic-gastrointestinal-disorders-across-the-ages-100249239","NCT02523118","OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages","A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)","OMEGA","Inclusion Criteria:\n\n* Males or females 3 years of age and older\n* Mucosal eosinophilia:\n\nEoE ≥ 15 eosinophils\u002FHPF in the distal or proximal esophagus EoG ≥ 30 eosinophils\u002FHPF in 5 HPF\\'s in the body and\u002For antrum EoN ≥ 53 eosinophils\u002FHPF in the duodenum and\u002For ≥ 56 eosinophils\u002FHPF in the jejunum and\u002For ileum EoC ≥ 84 eosinophils\u002FHPF from the transverse or descending colon and\u002For ≥ 32 eosinophils\u002FHPF from the rectosigmoid colon or a biopsy from any colonic location with ≥ 100 eosinophils\u002FHPF\n\n\\- Presence of symptoms is required for patients who are newly diagnosed but not required for patients who were previously diagnosed.\n\nExclusion Criteria:\n\n* History of intestinal surgery other than G tube placement\n* Enrolled in a blinded investigational study at the time of the first study visit\n* Have esophageal stricture (\\<3mm)\n* Have other identifiable causes for eosinophilia (except Inflammatory Bowel Disease): infections, Gastrointestinal (GI) cancer, other GI inflammatory disease (e.g., Ulcerative Colitis or Crohn\\'s Disease)","3 Years",{"count":65,"type":22},1350,"The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and\u002For colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.",[68,69,26,70,71],"Eosinophilic Gastrointestinal Disorders (EGIDs)","Eosinophilic Esophagitis","Eosinophilic Gastroenteritis","Eosinophilic Colitis","2025-09-11",{"date":74,"type":46},"2025-09-12",{"date":76,"type":46},"2015-07-17",{"date":78,"type":22},"2051-01-01",{"name":52,"class":53},19]